CCCC logo

CCCC
C4 Therapeutics Inc

2,524
Mkt Cap
$406.89M
Volume
1.25M
52W High
$3.95
52W Low
$1.21
PE Ratio
-3.11
CCCC Fundamentals
Price
$3.61
Prev Close
$3.68
Open
$3.67
50D MA
$2.86
Beta
1.99
Avg. Volume
3.1M
EPS (Annual)
-$1.27
P/B
1.63
Rev/Employee
$345,644.23
$30.23
Loading...
Loading...
News
all
press releases
Vishay Intertechnology, Eos Energy Enterprises, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday
Vishay Intertechnology (VSH) stock up 10%, Velo3D (VELO) up 35.5%, VNET (VNET) up 32.5%, C4 Therapeutics (CCCC) up 19.4%, Kingsoft Cloud (KC) up 18.6%, Tower Semiconductor (TSEM) up 17.5%, Nebius...
Benzinga·1d ago
News Placeholder
More News
News Placeholder
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +4.76% and -5.35%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2d ago
News Placeholder
LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of -20.00% and +15.21%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +27.04% and -15.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9d ago
News Placeholder
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update
C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling...
MarketBeat·15d ago
News Placeholder
Short Interest in C4 Therapeutics, Inc. (NASDAQ:CCCC) Grows By 19.4%
C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totaling 16,157,271 shares, an increase of 19.4% from the March 15th total of 13,534,910 shares. Approximately 18.1% of the...
MarketBeat·27d ago
News Placeholder
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven ratings firms that are presently covering the firm...
MarketBeat·27d ago
News Placeholder
C4 Therapeutics Deepens Roche Alliance To Target Breakthrough Cancer Therapies
C4 Therapeutics partners with Roche to develop cancer-fighting DACs. CCCC eligible for $1B+ in milestones plus royalties. See the details.read more...
Benzinga·1mo ago
News Placeholder
CCCC Stock Reverses Pre-Market Gains After Roche Tie-Up To Develop Cancer Treatments - Retail Sees Strong Upside
Under the agreement, C4 Therapeutics will receive a $20 million upfront payment and could earn over $1 billion in milestone payments.
Stocktwits·1mo ago
News Placeholder
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update
C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 13th, there was short interest totaling 13,534,910...
MarketBeat·2mo ago
<
1
2
...
>

Latest CCCC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.